The short version of mitochondrial biogenesis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-10 and is reviewed periodically as new material appears.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
=== LGBTQ+ rights === In 2019, Schmitt was among 14 Republican state attorneys general signatories who signed an amicus brief to the Supreme Court brief arguing that the Civil Rights Act of 1964 does not protect LGBTQ+ people from employment discrimination. In June 2020, the Supreme Court ruled 6–3 that employment discrimination on the basis of sexual orientation does violate the Civil Rights Act of 1964.
Phyllostachys nigra, commonly known as black bamboo or purple bamboo (Chinese: 紫竹), is a species of bamboo, native to Hunan Province of China, and is widely cultivated elsewhere. Growing up to 10 meters (35 ft) tall by 5cm (2 in) wide, it forms clumps of slender arching canes which turn black after two or three seasons. The abundant lance-shaped leaves are 4–13 cm (2–5 in) long. Numerous forms and cultivars are available for garden use. The species and the form P. nigra f. henonis have both gained the Royal Horticultural Society's Award of Garden Merit. The form henonis is also known as Henon bamboo and as cultivar 'Henon'.
Crosslinks are generated by a variety of exogenous and endogenous agents, including chemical compounds and high-energy radiation, and tend to interfere with normal cellular processes such as DNA replication and transcription, meaning their persistence usually compromises cell health.
The objectives of the Party of European Socialists, the European Parliament's social democratic bloc, are now "to pursue international aims in respect of the principles on which the European Union is based, namely principles of freedom, equality, solidarity, democracy, respect of Human Rights and Fundamental Freedoms, and respect for the Rule of Law." As a result, today the rallying cry of the French Revolution—Liberté, égalité, fraternité—is promoted as essential socialist values. To the left of the European Socialists at the European level is the Party of the European Left, a political party at the European level and an association of democratic socialist and communist parties in the European Union and other European countries. It was formed for the purposes of running in the 2004 European Parliament election. The European Left was founded on 8–9 May 2004 in Rome. Elected MEPs from member parties of the European Left sit in the European United Left–Nordic Green Left group in the European Parliament. The democratic socialist Left Party in Germany grew in popularity, as did popular dissatisfaction with the increasingly neoliberal policies of the Social Democratic Party of Germany after Gerhard Schröder's tenure as Chancellor, becoming the fourth biggest party in parliament in the general election on 27 September 2009. In 2008, the Progressive Party of Working People candidate Dimitris Christofias won a crucial presidential runoff in Cyprus, defeating his conservative rival with a majority of 53%.
acidic type I hair keratin type I hair keratin 1, KRT31 type I hair keratin 2, KRT32 type I hair keratin 3A, KRT33A type I hair keratin 3B, KRT33B type I hair keratin 4, KRT34 type I hair keratin 5, KRT35 type I hair keratin 6, KRT36 type I hair keratin 7, KRT37 type I hair keratin 8, KRT38 basic type II hair keratin type II hair keratin 1, KRT81 type II hair keratin 2, KRT82 type II hair keratin 3, KRT83 type II hair keratin 4, KRT84 type II hair keratin 5, KRT85 type II hair keratin 6, KRT86
Sources: en.wikipedia.org
Organised retail will need workers. Walmart employs 1.4 million people in United States alone. With United States population of about 300 million, and India's population of about 1200 million, if Walmart-like retail companies were to expand in India as much as their presence in the United States, and the staffing level in Indian stores kept at the same level as in the United States stores, Walmart alone would employ 5.6 million Indian citizens. Walmart has a 6.5% market share of the total United States retail. Adjusted for this market share, the expected jobs in future Indian organised retail would total over 85 million. In addition, millions of additional jobs will be created during the building of and the maintenance of retail stores, roads, cold storage centers, software industry, electronic cash registers and other retail supporting organisations. Instead of job losses, retail reforms are likely to be massive boost to Indian job availability. KPMG - one of the world's largest audit companies - finds that in China, the employment in both retail and wholesale trade increased from 4% in 1992 to about 7% in 2001, post China opening its retail to foreign and domestic innovation and competition. In absolute terms, China experienced the creation of 26 million new jobs within 9 years, post China announcing FDI retail reforms. Additionally, contrary to some concerns in China, post retail reforms, the number of traditional small retailers also grew by 30% over 5 years.
Manchester Museum organised a public discussion, "Should We Display the Dead?", which considered both Lindow Man and the Body Worlds exhibition then showing elsewhere in the city. A study by curators Jody Joy and Julia Farley examined 69 enquiries about Lindow Man received by British Museum curators between 2009 and 2018. Questions about the ethics of displaying his remains came mainly from students researching dissertations; none of the enquiries classified as coming from the general public raised that issue. Public enquiries instead tended to concern his life, death and scientific investigation. The authors distinguished these interests from the ethical questions prominent in academic and museum discussions.
=== New books === Titus Lewis & Joseph Harris (Gomer) - Y Drysorfa Efangylaidd William Richards - Address on the Duration or Perpetuity of Christian Baptism, with some Introductory Hints upon the Subjects and Mode of that Ordinance Thomas Roberts of Llwynrhudol - Amddiffyniad i'r Methodistiaid Charles Symmons - Life of Milton
tandem repeat A pattern within a nucleic acid sequence in which one or more nucleobases are repeated and the repetitions are directly adjacent (i.e. tandem) to each other. An example is ATGACATGACATGAC, in which the sequence ATGAC is repeated three times.
Zverev then made only modest achievements in the succeeding weeks, losing to Learner Tien in the second round of the Mexican Open, to Tallon Griekspoor in the second round of Indian Wells, to Arthur Fils in the fourth round of the Miami Open, and to Matteo Berrettini in Monte-Carlo. In April, Zverev won his 3rd title in Munich and 24th overall on his birthday, winning in straight sets over Ben Shelton. Zverev was presented his trophy BMW by Dominic Thiem, and reclaimed the world No. 2 ranking from Alcaraz. The next week, he reached the round of 16 at the Madrid Open. During his third round match, Zverev was given a code violation for taking a photo of the ball mark of shot which Zverev considered to have been erroneously called in. Later, social media posts from the ATP Tour suggested that the Hawk-Eye call was correct and that Zverev likely took a picture of a different mark. Following this, Zverev failed to defend either his titles in Rome and Hamburg with a straight sets loss against an in-form Lorenzo Musetti and a three-set loss against Alexandre Müller, respectively. At the French Open where he was defending finalist points, Zverev advanced to the quarterfinals, where he was defeated by Novak Djokovic in a four-set match. On the grass, Zverev reached his third final of the year in Stuttgart, losing to Taylor Fritz in straight sets in his fifth consecutive loss against the American. He then reached the semifinals against Daniil Medvedev in Halle, losing in three sets.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.